213 related articles for article (PubMed ID: 21274871)
41. Down-regulated PLAC8 promotes hepatocellular carcinoma cell proliferation by enhancing PI3K/Akt/GSK3β/Wnt/β-catenin signaling.
Zou L; Chai J; Gao Y; Guan J; Liu Q; Du JJ
Biomed Pharmacother; 2016 Dec; 84():139-146. PubMed ID: 27643556
[TBL] [Abstract][Full Text] [Related]
42. FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
Fang F; Yang L; Tao Y; Qin W
Cancer; 2012 Jan; 118(1):134-46. PubMed ID: 21713761
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
[TBL] [Abstract][Full Text] [Related]
44. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma.
Shi GM; Ke AW; Zhou J; Wang XY; Xu Y; Ding ZB; Devbhandari RP; Huang XY; Qiu SJ; Shi YH; Dai Z; Yang XR; Yang GH; Fan J
Hepatology; 2010 Jul; 52(1):183-96. PubMed ID: 20578262
[TBL] [Abstract][Full Text] [Related]
45. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
46. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway.
Xu J; Zhu X; Wu L; Yang R; Yang Z; Wang Q; Wu F
Liver Int; 2012 May; 32(5):752-60. PubMed ID: 22276989
[TBL] [Abstract][Full Text] [Related]
48. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.
Zhou HH; Chen L; Liang HF; Li GZ; Zhang BX; Chen XP
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110775
[TBL] [Abstract][Full Text] [Related]
49. A natural antisense transcript regulates acetylcholinesterase gene expression via epigenetic modification in Hepatocellular Carcinoma.
Xi Q; Gao N; Zhang X; Zhang B; Ye W; Wu J; Zhang X
Int J Biochem Cell Biol; 2014 Oct; 55():242-51. PubMed ID: 25240585
[TBL] [Abstract][Full Text] [Related]
50. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.
Wang J; Sun J; Zhang N; Yang R; Li H; Zhang Y; Chen K; Kong D
Life Sci; 2019 Feb; 219():182-189. PubMed ID: 30630006
[TBL] [Abstract][Full Text] [Related]
51. Oleuropein induces apoptosis via activation of caspases and suppression of phosphatidylinositol 3-kinase/protein kinase B pathway in HepG2 human hepatoma cell line.
Yan CM; Chai EQ; Cai HY; Miao GY; Ma W
Mol Med Rep; 2015 Jun; 11(6):4617-24. PubMed ID: 25634350
[TBL] [Abstract][Full Text] [Related]
52. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling.
Chen J; Chan AW; To KF; Chen W; Zhang Z; Ren J; Song C; Cheung YS; Lai PB; Cheng SH; Ng MH; Huang A; Ko BC
Hepatology; 2013 Jun; 57(6):2287-98. PubMed ID: 23348706
[TBL] [Abstract][Full Text] [Related]
53. Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma.
Lv X; Zhao F; Huo X; Tang W; Hu B; Gong X; Yang J; Shen Q; Qin W
Med Oncol; 2016 Jul; 33(7):70. PubMed ID: 27262566
[TBL] [Abstract][Full Text] [Related]
54. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway.
Huang Y; Liu C; Zeng WC; Xu GY; Wu JM; Li ZW; Huang XY; Lin RJ; Shi X
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840737
[TBL] [Abstract][Full Text] [Related]
55. Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal‑regulated kinase signaling pathway.
Zhang ZG; Qin CY
Mol Med Rep; 2014 Mar; 9(3):882-8. PubMed ID: 24366394
[TBL] [Abstract][Full Text] [Related]
56. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH
Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379
[TBL] [Abstract][Full Text] [Related]
57. DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/β-catenin signaling.
Liu Y; Zhou R; Yuan X; Han N; Zhou S; Xu H; Guo M; Yu S; Zhang C; Yin T; Wu K
Oncotarget; 2015 Apr; 6(11):8621-34. PubMed ID: 25940701
[TBL] [Abstract][Full Text] [Related]
58. TRIP6 promotes cell proliferation in hepatocellular carcinoma via suppression of FOXO3a.
Zhao W; Dai Y; Dai T; Xie T; Su X; Li J; Zhou X; Meng K; Zhao X
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):594-601. PubMed ID: 29080747
[TBL] [Abstract][Full Text] [Related]
59. Acetylcholinesterase is associated with a decrease in cell proliferation of hepatocellular carcinoma cells.
Pérez-Aguilar B; Vidal CJ; Palomec G; García-Dolores F; Gutiérrez-Ruiz MC; Bucio L; Gómez-Olivares JL; Gómez-Quiroz LE
Biochim Biophys Acta; 2015 Jul; 1852(7):1380-7. PubMed ID: 25869328
[TBL] [Abstract][Full Text] [Related]
60. Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression.
Wen W; Ding J; Sun W; Fu J; Chen Y; Wu K; Ning B; Han T; Huang L; Chen C; Xie D; Li Z; Feng G; Wu M; Xie W; Wang H
Hepatology; 2012 Jun; 55(6):1787-98. PubMed ID: 22271581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
